32 -5 (91) 2026 - Abdullaev Sh.S., Xaydarova N.B. - STRATEGIES FOR STRATIFICATION AND MANAGEMENT OF PATIENTS WITH MALVAD: INTERNATIONAL GUIDELINES AND CLINICAL PRACTICE REALITIES

STRATEGIES FOR STRATIFICATION AND MANAGEMENT OF PATIENTS WITH MALVAD: INTERNATIONAL GUIDELINES AND CLINICAL PRACTICE REALITIES

Abdullaev Sh.S. - Andijan State Medical Institute

Xaydarova N.B. - Andijan State Medical Institute

Niyazov Z.M. - Andijan State Medical Institute

Kasimova N.Dj. - Andijan State Medical Institute

Yunusova Z.V. - Andijan State Medical Institute

Resume

Current international guidelines for the management of patients with MAFLD are based on early risk stratification of disease progression using non-invasive methods such as FIB-4, NAFLD fibrosis score, and elastography. The main focus is on identifying patients at high risk of advanced fibrosis and cardiometabolic complications. Management strategies include lifestyle modification (weight reduction, physical activity), control of metabolic risk factors (insulin resistance, dyslipidemia, arterial hypertension), and treatment of associated conditions. Despite established international recommendations, real-world clinical practice still faces challenges related to early diagnosis and adequate risk stratification. Improving patient management requires the implementation of screening programs and a multidisciplinary approach.

Keywords: Metabolic dysfunction-associated fatty liver disease (MAFLD); risk stratification; international guidelines; FIB-4; NAFLD fibrosis score; elastography; non-invasive assessment; lifestyle modification; cardiometabolic risk; multidisciplinary management.

First page

187

Last page

190

For citation:Abdullaev Sh.S., Xaydarova N.B., Niyazov Z.M. Kasimova N.Dj., Yunusova Z.V. - STRATEGIES FOR STRATIFICATION AND MANAGEMENT OF PATIENTS WITH MALVAD: INTERNATIONAL GUIDELINES AND CLINICAL PRACTICE REALITIES//New Day in Medicine 5(91)2026 187-190 https://newdayworldmedicine.com/en/new_day_medicine/5-91-2026

List of References

1. Alferink LJ, Erler NS, Bosschieter JN, de Knegt RJ, Metselaar HJ, Janssen HLA, et al. Associations between dietary macronutrient intake and liver steatosis and fibrosis: a population-based study. Hepatology. 2019;69(6):2355–2367. DOI:10.1002/hep.30490.
2. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202–209. DOI:10.1016/j.jhep.2020.03.039.
3. Eslam M, Sanyal AJ, George J. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158(7):1999–2014. DOI:10.1053/j.gastro.2019.11.312.
4. Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States. J Hepatol. 2022;77(3):682–697. DOI:10.1016/j.jhep.2022.04.037.
5. Kanehisa H, Fukunaga T, et al. Muscle size, strength, and metabolic parameters in Japanese sumo wrestlers. J Physiol Anthropol. 2019;38(1):6. DOI:10.1186/s40101-019-0190-2.
6. Mantovani A, Byrne CD, Zheng MH, Targher G. Risk of Nonalcoholic Fatty Liver Disease in Individuals With Type 1 Diabetes: A Meta-analysis. Diabetes Care. 2021;44(2):480–487. DOI:10.2337/dc20-1930.
7. Mazidi M, Kengne AP, Banach M. Dietary inflammatory index and cardiometabolic risk in US adults. Atherosclerosis. 2018;276:23–27. DOI:10.1016/j.atherosclerosis.2018.07.009.
8. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20. DOI:10.1038/nrgastro.2017.109.

   file

   download